Absent MicroRNAs in Different Tissues of Patients with Acquired Cardiomyopathy

Abstract

MicroRNAs (miRNAs) can be found in a wide range of tissues and body fluids, and their specific signatures can be used to determine diseases or predict clinical courses. The miRNA profiles in biological samples (tissue, serum, peripheral blood mononuclear cells or other body fluids) differ significantly even in the same patient and therefore have their own specificity for the presented condition. Complex profiles of deregulated miRNAs are of high interest, whereas the importance of non-expressed miRNAs was ignored. Since miRNAs regulate gene expression rather negatively, absent miRNAs could indicate genes with unaltered expression that therefore are normally expressed in specific compartments or under specific disease situations. For the first time, non-detectable miRNAs in different tissues and body fluids from patients with different diseases (cardiomyopathies, Alzheimer’s disease, bladder cancer, and ocular cancer) were analyzed and compared in this study. miRNA expression data were generated by microarray or TaqMan PCR-based platforms. Lists of absent miRNAs of primarily cardiac patients (myocardium, blood cells, and serum) were clustered and analyzed for potentially involved pathways using two prediction platforms, i.e., miRNA enrichment analysis and annotation tool (miEAA) and DIANA miRPath. Extensive search in biomedical publication databases for the relevance of non-expressed miRNAs in predicted pathways revealed no evidence for their involvement in heart-related pathways as indicated by software tools, confirming proposed approach.

micro-RNAs dependent regulation of DNMT and HIF1α gene expression in thrombotic disorders

“…Subsequently, we performed enrichment analysis with the help of miRNA Enrichment Analysis and Annotation (miEAA) tool. This tool has been previously utilized for clustering and analyzing the miRNAs for potential pathways involved in acquired cardiomyopathy 45 . The tool scrutinizes the list of over and underexpressed miRNAs from the published datasets and observes potential association between diseases and pathways.…”

Novel Anti Double-Stranded Nucleic Acids Full-Length Recombinant Camelid Heavy-Chain Antibody for the Detection of miRNA

“…As a part of the RNA-induced silencing complex (RISC), they bind complementary imperfect mRNA sequences thus modulating or silencing the activity of their mRNA targets [ 1 ]. Altered miRNA profiles have been discovered in multiple tissues and body fluids, that have been associated with the onset, progress, and prognosis of several serious diseases such as cancer, neurological disorders, and cardiovascular and myocardial diseases [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. In association with inflammatory and virally induced cardiomyopathies and dilated cardiomyopathy (DCM), the miRNAs homo sapiens (hsa)-let-7f-5p, hsa-miR-30a-3p, hsa-miR-93-5p, hsa-miR-197-3p, hsa-miR-223, and hsa-miR-379-5p showed an altered expression profile [ 7 , 10 ].…”

“…Altered miRNA profiles have been discovered in multiple tissues and body fluids, that have been associated with the onset, progress, and prognosis of several serious diseases such as cancer, neurological disorders, and cardiovascular and myocardial diseases [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ]. In association with inflammatory and virally induced cardiomyopathies and dilated cardiomyopathy (DCM), the miRNAs homo sapiens (hsa)-let-7f-5p, hsa-miR-30a-3p, hsa-miR-93-5p, hsa-miR-197-3p, hsa-miR-223, and hsa-miR-379-5p showed an altered expression profile [ 7 , 10 ]. There is rising interest in elucidating miRNA expression patterns and their functions because they represent promising second-generation biomarkers for new diagnostic approaches under physiological and pathophysiological conditions.…”

Targeting of miR-432 to myozenin1 to regulate myoblast proliferation and differentiation

“…For example, miR-1, miR-133, miR-206, and miR-208 regulate transcriptional networks that include serum response factor, myocyte enhancer factor-2, and myocardin and thereby regulate myoblast proliferation and differentiation during myogenesis (Bostjancic et al, 2010;Belevych et al, 2011;Lee et al, 2013). Indeed, aberrant miRNA expression has been observed in certain muscle diseases, including cardiac and skeletal muscle hypertrophy, heart failure, and muscular dystrophy (Siegismund et al, 2016).…”